TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11778111
Drug: Ropivacaine 0.5%
Normalized name: ROPivacaine 0.5% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 0.5% combined with morphine 2 mg (group M)
Study: 11778111
Drug: Ropivacaine 0.2%
Normalized name: ROPivacaine 0.2% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 0.2% plus sufentanil 0.5 mcg/ml (group S)
Study: 11778111
Drug: Ropivacaine 0.2%
Normalized name: ROPivacaine 0.2% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 0.2% plus morphine 0.02 mg/ml (group M)
Study: 9596230
Drug: Frequent aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Frequent aspirin use
Study: 9596230
Drug: Infrequent aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Infrequent aspirin use
Study: 9596230
Drug: Aspirin use
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin use (frequent and infrequent)
Study: 2576364
Drug: Picumast dihydrochloride
Normalized name: Levocetirizine Dihydrochloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Picumast dihydrochloride (2 mg o.d.)
Study: 1278006
Drug: Forced water
Approvals — FDA: no, EMA: no, PMDA: no
Description: Forced water diuresis (oral or parenteral fluid)
Study: 1278006
Drug: Furosemide in
Normalized name: furosemide Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Furosemide in high dosage
Study: 23597577
Drug: Atorvastatin 80
Normalized name: atorvastatin 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 80 mg daily for 7 days prior to PCI
Study: 22090167
Drug: Colchicine 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colchicine 1.0 mg twice daily starting on postoperative day 3 followed by a maintenance dose of 0.5 mg twice daily for 1 month (doses halved for patients <70 kg or intolerant)
Study: 9935260
Drug: Trovafloxacin (intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trovafloxacin (intravenous alatrofloxacin followed by oral trovafloxacin for a maximum of 14 days)
Study: 9935260
Drug: Cefoxitin followed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefoxitin followed by amoxicillin/clavulanic acid (control group)
Study: 15374296
Drug: CDP-choline 1000
Normalized name: CDP-choline
DrugBank: Citicoline (DB12153)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CDP-choline 1000 mg/day i.m.
Study: 2907743
Drug: Metoprolol (low-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol (low-dose beta-blockade starting with 6.25 mg twice daily, increasing to a maximum of 100 mg as tolerated)
Study: 2907743
Drug: Placebo (relative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (relative placebo group receiving standard therapy including digitalis, diuretics, vasodilators, and anticoagulants as needed)
Study: 26370724
Drug: 2 mL
Normalized name: ethanol 2 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mL of 2% lidocaine with epinephrine
Study: 25160518
Drug: Once-daily tacrolimus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily tacrolimus extended release (Tac-ER)
Study: 25160518
Drug: Twice-daily tacrolimus
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice-daily tacrolimus immediate release (Tac-IR)
Study: 22268509
Drug: Single-plane treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-plane treatment with 4.0 MHz, 4.5-mm depth transducer
Study: 22268509
Drug: Dual-plane treatment
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual-plane treatment with 4.0 MHz, 4.5-mm depth followed by 7.0 MHz, 3.0-mm depth transducer
Study: 22268509
Drug: Both single-plane
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both single-plane and dual-plane treatments
Study: 19281927
Drug: rHDL (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: rHDL (80 mg/kg of apolipoprotein A-I)
Study: 12237626
Drug: Fluoxetine with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine with oral contraceptives
Study: 12237626
Drug: Fluoxetine without
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine without oral contraceptives
Study: 9842788
Drug: Fluvoxamine (50-300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvoxamine (50-300 mg)
Study: 7989026
Drug: HMO members
Normalized name: nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: HMO members receiving antipsychotic drugs or lithium
Study: 30987658
Drug: Songling Xuemaikang
Approvals — FDA: no, EMA: no, PMDA: no
Description: Songling Xuemaikang capsules (SXC)
Study: 28834608
Drug: Factors associated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Factors associated with verification at 10 ng/ml
Study: 26332857
Drug: Dexmedetomidine (DEX)
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexmedetomidine (DEX) 0.5 μg·kg IV bolus
Study: 23320520
Drug: AZD1386 (95
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD1386 (95 mg single dose)
Study: 15146408
Drug: COBRA therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: COBRA therapy (including temporary high-dose prednisolone, temporary low-dose methotrexate, and sulfasalazine)
Study: 11535840
Drug: 0.2 percent
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 percent nitroglycerin ointment (n = 19)
Study: 8294171
Drug: Nalbuphine 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nalbuphine 0.3 mg.kg-1
Study: 26709060
Drug: Ezetimibe and
Normalized name: Ezetimibe and Simvastatin Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ezetimibe and low-dose simvastatin
Study: 23597333
Drug: Expectancy group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Expectancy group (placebo cream applied)
Study: 23597333
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no placebo cream applied)
Study: 16672069
Drug: PSQ-An Treatment
Normalized name: Aldex AN
DrugBank: Doxylamine (DB00366)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PSQ-An Treatment burden subscale
Study: 11008329
Drug: Fosinopril (5-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fosinopril (5-20 mg/day)
Study: 11008329
Drug: No ACE-inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: No ACE-inhibitor therapy (Control group)
Study: 9103725
Drug: Cognitive therapy
Normalized name: cognitive therapy software
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive therapy (16 weekly sessions)
Study: 9103725
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment (6-12 weeks)
Study: 8095251
Drug: Verapamil 240
Normalized name: verapamil 240 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil 240 mg (once a day)
Study: 8095251
Drug: Captopril 20
Normalized name: Captopril
DrugBank: Captopril (DB01197)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Captopril 20 mg (twice a day)
Study: 3527720
Drug: Bay m
Normalized name: ZINC OXIDE 94 mg in 1 mL TOPICAL LOTION [Cay Skin MoBay Mineral Sunscreen Drops SPF 30]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bay m 1099 (100 mg before breakfast and dinner)
Study: 29763657
Drug: mHealth-based care
Approvals — FDA: no, EMA: no, PMDA: no
Description: mHealth-based care model (daily BP measurement using smartphone and wireless BP monitor, bi-weekly medication adjustments)
Study: 20070849
Drug: Cognitive-behavioral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral therapy (CBT) intervention for panic symptoms
Study: 16372827
Drug: Onercept 5mg
Normalized name: Onercept
DrugBank: Onercept (DB06495)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Onercept 5mg and 50mg (single intravenous doses)
Study: 16372827
Drug: Onercept 15mg
Normalized name: Onercept
DrugBank: Onercept (DB06495)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Onercept 15mg and 150mg (single intravenous doses)
Study: 16372827
Drug: Onercept 50mg
Normalized name: Onercept
DrugBank: Onercept (DB06495)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Onercept 50mg (single intravenous, subcutaneous and intramuscular doses)
Study: 16372827
Drug: Onercept 50mg
Normalized name: Onercept
DrugBank: Onercept (DB06495)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Onercept 50mg (repeat subcutaneous administration of six doses every 48 hours)
Study: 16372827
Drug: Onercept 100mg
Normalized name: Onercept
DrugBank: Onercept (DB06495)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Onercept 100mg and 150mg (repeat subcutaneous administration of six doses over 2 weeks)
Study: 11235499
Drug: New nonprescription
Approvals — FDA: no, EMA: no, PMDA: no
Description: New nonprescription medication
Study: 9703836
Drug: 5-FU 250
Normalized name: 5-FU 250 MG Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-FU 250 mg/day with Limethason 1 A (4.0 mg of dexamethasone palmitate) in Group B
Study: 9703836
Drug: 5-FU 250
Normalized name: 5-FU 250 MG Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-FU 250 mg/day in Group A
Study: 7816530
Drug: Diuretics treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diuretics treatment in infants with congenital heart disease
Study: 3050936
Drug: Ketanserin 40
Normalized name: ketanserin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketanserin 40 mg single dose
Study: 3050936
Drug: Ketanserin 20
Normalized name: ketanserin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketanserin 20 mg b.d. chronic dosing
Study: 3050936
Drug: Ketanserin 40
Normalized name: ketanserin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketanserin 40 mg b.d. chronic dosing
Study: 3050936
Drug: Ketanserin mean
Normalized name: ketanserin
DrugBank: Ketanserin (DB12465)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketanserin mean dose 73 mg/day for 7 weeks
Study: 3050936
Drug: Ketanserin mean
Normalized name: ketanserin
DrugBank: Ketanserin (DB12465)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketanserin mean dose 167 mg/day
Study: 25879460
Drug: Tadalafil 5
Normalized name: tadalafil 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tadalafil 5 mg OaD
Study: 25879460
Drug: Tadalafil 20
Normalized name: tadalafil 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tadalafil 20 mg PRN
Study: 19223620
Drug: IPTi-SP (sulfadoxine-pyrimethamine)
Normalized name: SPS
Approvals — FDA: no, EMA: no, PMDA: no
Description: IPTi-SP (sulfadoxine-pyrimethamine) administered at 3, 9, and 15 months of age
Study: 15031611
Drug: All treatments
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All treatments (E20, L10, P)
Study: 11180494
Drug: Bright light
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bright light therapy combined with placebo
Study: 11180494
Drug: Bright light
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bright light therapy combined with melatonin
Study: 9663225
Drug: Adjunctive subconjunctival
Normalized name: lincomycin
DrugBank: Lincomycin (DB01627)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adjunctive subconjunctival mitomycin C (MMC) during primary glaucoma triple procedure
Study: 9663225
Drug: Adjunctive subconjunctival
Normalized name: lincomycin
DrugBank: Lincomycin (DB01627)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adjunctive subconjunctival mitomycin C (MMC) for 3 minutes
Study: 9663225
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no adjunctive mitomycin C)
Study: 7829176
Drug: 0.03% flurbiprofen,
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.03% flurbiprofen, administered 6 times at 15 minute intervals 90 minutes preoperatively in addition to the routine dilation regimen.
Study: 7829176
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no flurbiprofen treatment).
Study: 3278412
Drug: CDP-choline (1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: CDP-choline (1,000 mg/day i.v. once daily for 14 days)
Study: 31230026
Drug: 6-month supervised
Normalized name: leuprolide
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6-month supervised training courses (weekly gym training and Taiji sessions), followed by a free 6-month unsupervised use of exercise facilities, and unsupervised low-cost exercise for another 12 months
Study: 29151036
Drug: Initial combination
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Initial combination therapy (losartan 50-100 mg plus hydrochlorothiazide 12.5-25 mg)
Study: 29151036
Drug: Initial monotherapy
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Initial monotherapy (losartan 50-100 mg or hydrochlorothiazide 12.5-25 mg)
Study: 29151036
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (losartan 100 mg and hydrochlorothiazide 12.5 to 25 mg) in phase 2
Study: 21604900
Drug: 40-session cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40-session cognitive treatment
Study: 9713471
Drug: CDDP‐MS containing
Approvals — FDA: no, EMA: no, PMDA: no
Description: CDDP‐MS containing 200 mg of cisplatin (n = 5)
Study: 9713471
Drug: CDDP‐S containing
Approvals — FDA: no, EMA: no, PMDA: no
Description: CDDP‐S containing 100 mg of cisplatin (n = 10)
Study: 8148215
Drug: Oxcarbazepine (OXC)
Normalized name: Oxcarbazepine
DrugBank: Oxcarbazepine (DB00776)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxcarbazepine (OXC) 600 mg single dose followed by 300 mg thrice daily for 3 weeks
Study: 8148215
Drug: Oxcarbazepine (OXC)
Normalized name: Oxcarbazepine
DrugBank: Oxcarbazepine (DB00776)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxcarbazepine (OXC) 300 mg thrice daily for 3 weeks
Study: 8148215
Drug: Oxcarbazepine (OXC)
Normalized name: Oxcarbazepine
DrugBank: Oxcarbazepine (DB00776)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxcarbazepine (OXC) as add-on therapy
Study: 2454440
Drug: Opioids (morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Opioids (morphine or equivalent doses)
Study: 30529378
Drug: Crestal implants
Normalized name: Crystal ammonia
DrugBank: Ammonium carbonate (DB15926)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crestal implants (placed approximately 2 mm below the bone crest)
Study: 30529378
Drug: Subcrestal implants
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcrestal implants (placed at bone crest level)
Study: 22925498
Drug: Hyaluronic acid-9
Normalized name: hyaluronic acid
DrugBank: Hyaluronic acid (non-animal stabilized) (DB19175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hyaluronic acid-9 group (4 weekly instillations of 40 mg followed by 5 monthly instillations)
Study: 22925498
Drug: Hyaluronic acid-12
Normalized name: hyaluronic acid
DrugBank: Hyaluronic acid (non-animal stabilized) (DB19175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hyaluronic acid-12 group (12 instillations of 40 mg every 2 weeks)
Study: 16506061
Drug: Placebo (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (6 mg)
Study: 15585783
Drug: Short-chain fructooligosaccharides
Normalized name: fructooligosaccharide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short-chain fructooligosaccharides (10 g/d)
Study: 15585783
Drug: Soybean oligosaccharides
Normalized name: SOYBEAN
DrugBank: Soybean (DB10568)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soybean oligosaccharides (10 g/d)
Study: 15585783
Drug: Galactooligosaccharides (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Galactooligosaccharides (10 g/d)
Study: 15585783
Drug: Type III
Normalized name: Collagen type III
Approvals — FDA: no, EMA: no, PMDA: no
Description: Type III resistant starch (10 g/d)
Study: 15585783
Drug: NDCHs (2.5,
Approvals — FDA: no, EMA: no, PMDA: no
Description: NDCHs (2.5, 5.0, 7.5, or 10 g/d)
Study: 11760223
Drug: Nelfinavir suspension
DrugBank: Nelfinavir (DB00220)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nelfinavir suspension (1250 mg in 100 mL of water)
Study: 11760223
Drug: Nelfinavir tablets
Normalized name: Nelfinavir Tablets
DrugBank: Nelfinavir (DB00220)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nelfinavir tablets (five 250-mg tablets)
Study: 11760223
Drug: Nelfinavir suspension
DrugBank: Nelfinavir (DB00220)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nelfinavir suspension
Study: 3811814
Drug: Ketamine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine infusion (30 mg i.v. bolus followed by 1 mg/min for 8 hours)
Study: 26846333
Drug: Roxadustat (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Roxadustat (1.5 to 2.0 mg/kg)
Study: 26846333
Drug: Roxadustat (2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Roxadustat (2.0 mg/kg)
Study: 17963858
Drug: Contraceptive vaginal
Normalized name: VCF 4% Contraceptive Vaginal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contraceptive vaginal ring (RING) releasing 15 mcg ethinyl estradiol and 120 mcg etonogestrel per day
Study: 17963858
Drug: Low-dose oral
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose oral contraceptive (PILL) containing 20 mcg ethinyl estradiol and 100 mcg levonorgestrel daily
Study: 10365352
Drug: Twice weekly
Normalized name: Alora 0.1 MG/Day Twice Weekly Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice weekly supervised oral iron administration (group B)
Study: 10365352
Drug: Daily unsupervised
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily unsupervised oral iron administration (group A)
Study: 10365352
Drug: Parenteral iron
Normalized name: Iron, parenteral preparations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral iron (group C)
Study: 26773735
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment for standard-risk ALL
Study: 25547786
Drug: Levofloxacin-based triple
Normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Levofloxacin-based triple therapy (LAL): levofloxacin 500 mg daily, amoxicillin 1 g b.i.d., lansoprazole 30 mg b.i.d. for 10 days
Study: 25547786
Drug: Moxifloxacin-based triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxifloxacin-based triple therapy (MAL): moxifloxacin 400 mg daily, amoxicillin 1 g b.i.d., lansoprazole 30 mg b.i.d. for 10 days
Study: 25547786
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (CAL): clarithromycin 500 mg b.i.d., amoxicillin 1 g b.i.d., lansoprazole 30 mg b.i.d.
Study: 1680982
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy (hydralazine + sorbitrate)
Study: 17542352
Drug: Generic oral
Normalized name: Generlac Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Generic oral solution of risperidone (1 mg)
Study: 17542352
Drug: Risperdal tablets
Normalized name: Risperdal
DrugBank: Risperidone (DB00734)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Risperdal tablets (1 mg)
Study: 15356547
Drug: Medication treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication treatment for asthma
Study: 12297482
Drug: Parenteral nutrition
Normalized name: parenteral nutrition solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral nutrition supplemented with 20 g/d L-arginine for 7 days
Study: 9708936
Drug: Chemotherapy supported
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy supported with G‐CSF (5 microg/kg subcutaneously on Days 2‐13; Arm B)
Study: 9708936
Drug: Chemotherapy supported
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy supported with G‐CSF (Arm B)
Study: 19481229
Drug: Red wine
Normalized name: Red wine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Red wine (118 mL daily for 6 months)
Study: 19481229
Drug: White wine
Normalized name: White wine
Approvals — FDA: no, EMA: no, PMDA: no
Description: White wine (118 mL daily for 6 months)
Study: 7974677
Drug: 7.5 mg
Normalized name: biotin 7.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5 mg chlorproguanil daily
Study: 7974677
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg proguanil daily
Study: 7974677
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg chlorproguanil weekly
Study: 7974677
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg calcium lactate weekly (placebo)
Study: 409052
Drug: Disodium cromoglycate
Normalized name: Disodium cromoglycate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Disodium cromoglycate 10 mg, four times a day
Study: 31860534
Drug: L-Citrulline (CIT)
DrugBank: Citrulline (DB00155)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: L-Citrulline (CIT) 6 g·d for 7 days
Study: 31860534
Drug: L-Citrulline (CIT)
DrugBank: Citrulline (DB00155)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: L-Citrulline (CIT)
Study: 30971596
Drug: Magnesium sulfate
Normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Magnesium sulfate infusion at 15 mg/kg/h
Study: 11360129
Drug: Beta-carotene (42
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-carotene (42 mg)
Study: 9245870
Drug: Teicoplanin administered
Normalized name: teicoplanin
DrugBank: Teicoplanin (DB06149)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teicoplanin administered to half the patients at the start of the procedure
Study: 30354397
Drug: Omega-3 therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega-3 therapy (4 mg/d for 310±87 days)
Study: 30354397
Drug: Omega-3 therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega-3 therapy
Study: 27184297
Drug: Control Therapy
Normalized name: Benzoyl Peroxide;Salicylic Acid;Vitamin E 8%; 2%; 5% Topical application Kit [INOVA 8/2 ACNE CONTROL THERAPY]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control Therapy
Study: 24968280
Drug: Liquid protein
Normalized name: ProMod Liquid Protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liquid protein snack containing 30 g carbohydrates and 30 g proteins (casein, whey protein or an equal mix of the two; n 26-28 per group)
Study: 24968280
Drug: Control snack
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control snack containing 60 g maltodextrin
Study: 12814458
Drug: Gliclazide 80
Normalized name: gliclazide 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gliclazide 80 mg BID for 4 weeks
Study: 12814458
Drug: Glimepiride 2
Normalized name: glimepiride 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glimepiride 2 mg OD for 4 weeks
Study: 8859194
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose leucovorin (20 mg/m2/day by intravenous bolus) and 5-fluorouracil (425-600 mg/m2/day for 5 consecutive days every 28 days)